Page last updated: 2024-12-06

levomethadone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

levomethadone : A 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (R)-configuration. It is the active enantiomer of methadone and its hydrochloride salt is used to treat adults who are addicted to drugs such as heroin and morphine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID22267
CHEMBL ID159659
CHEBI ID136003
SCHEMBL ID147864

Synonyms (56)

Synonym
BIDD:PXR0190
(6r)-6-dimethylamino-4,4-di(phenyl)heptan-3-one
gtpl1605
levomethadonum [inn-latin]
levomethadone [inn]
brn 3213668
3-hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (r)-
(r)-6-(dimethylamino)-4,4-diphenyl-3-hetpanone
levometadona [inn-spanish]
PDSP2_000583
(-)-methadone
(6r)-methadone
d-(-)-methadone
l-polamivet
levomethadone
3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, l-
l-6-(dimethylamino)-4,4-diphenyl-3-heptanone
(-)-(r)-methadone
(r)-6-(dimethylamino)-4,4-diphenyl-3-heptanone
3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6r)- (9ci)
3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, (r)-
3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, l- (8ci)
polamivet
l-polamidon
125-58-6
3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6r)-
(-)-(r)-6-(dimethylamino)-4,4-diphenyl-3-heptanone
(r)-methadone
l-methadone
3-hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (r)- (9ci)
levadone
r-(-)-methadone
levothyl
PDSP1_000586
CHEBI:136003
(6r)-6-(dimethylamino)-4,4-diphenylheptan-3-one
levomethadone (inn)
D08121
methadone, l-
CHEMBL159659
A838934
(6r)-6-(dimethylamino)-4,4-diphenyl-3-heptanone
(6r)-6-(dimethylamino)-4,4-diphenyl-heptan-3-one
unii-6y75z4e8ns
6y75z4e8ns ,
levometadona
levomethadonum
3-14-00-00278 (beilstein handbook reference)
SCHEMBL147864
52310-03-9
heptanone, 6-(dimethylamino)-4,4-diphenyl-, l-
levomethadone [who-dd]
DB13515
bdbm50223633
Q6535776
DTXSID701016376

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"This trial was aimed to estimate the pharmacokinetic interaction between voriconazole and methadone at steady state in male patients on methadone therapy and to characterize the safety and tolerability profile during the coadministration."( Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
Foster, G; Labadie, R; Liu, P; Sharma, A; Somoza, E, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antitussiveAn agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mu-opioid receptor agonistA compound that exhibits agonist activity at the mu-opioid receptor.
NMDA receptor antagonistAny substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
6-(dimethylamino)-4,4-diphenylheptan-3-oneA ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1346364Human mu receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346329Human kappa receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346361Human delta receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID278718Dose normalized AUC (0-24h) in opiate abstinence syndrome patient at 30 to 100 mg, po QD after 2 days2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
AID148466Evaluated for analgesic activity as effective dose1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Conformation-activity study of methadone and related compounds.
AID150401Inhibition of [3H]- naloxone binding to Opioid receptors in rat brain membrane in the absence of Na1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists.
AID278722Cmax in opiate abstinence syndrome patient at 30 to 100 mg, po QD after 2 days2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
AID278721AUC (0-24h) in opiate abstinence syndrome patient at 30 to 100 mg, po QD after 2 days2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
AID278720Dose normalized Tmax in opiate abstinence syndrome patient at 30 to 100 mg, po QD after 2 days2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
AID150402Compound was evaluated for the inhibition of [3H]- naloxone binding to Opioid receptors in rat brain membrane in the presence of Na1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists.
AID278719Dose normalized Cmax in opiate abstinence syndrome patient at 30 to 100 mg, po QD after 2 days2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
AID278723Cmin in opiate abstinence syndrome patient at 30 to 100 mg, po QD after 2 days2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]